Duality Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History

Duality Advisers’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-20,608	Closed	-$2.48M	–	271
2024 Q1	$2.48M	Sell	20,608 -5,033	-20%	-$616K	0.24%	142
2023 Q4	$3.15M	Buy	25,641 +6,758	+36%	+$843K	0.33%	93
2023 Q3	$2.44M	Buy	18,883 +388	+2%	+$51.7K	0.3%	115
2023 Q2	$2.29M	Buy	+18,495	New	+$2.49M	0.29%	130
2022 Q4	–	Sell	-20,672	Closed	-$2.75M	–	680
2022 Q3	$2.75M	Buy	+20,672	New	+$3.14M	0.3%	121
2022 Q1	–	Sell	-3,524	Closed	-$449K	–	728
2021 Q4	$449K	Buy	+3,524	New	+$463K	0.05%	411
2021 Q3	–	Sell	-2,930	Closed	-$520K	–	625
2021 Q2	$520K	Sell	2,930 -5,968	-67%	-$1.03M	0.05%	430
2021 Q1	$1.46M	Buy	8,898 +6,077	+215%	+$1,000K	0.13%	277
2020 Q4	$466K	Buy	+2,821	New	+$420K	0.03%	448

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Duality Advisers's JAZZ Position: Q2 2024 in Review

Duality Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 20,608 shares — an estimated $2.48M sold.

Duality Advisers first reported a position in JAZZ in Q4 2020 and held it in 9 quarters. The position peaked at $3.15M in Q4 2023. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

Duality Advisers reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Duality Advisers sold 20,608 Jazz Pharmaceuticals shares in Q2 2024, an estimated $2.48M.
Duality Advisers first reported a position in Jazz Pharmaceuticals in Q4 2020 and held it in 9 quarters.
Duality Advisers's Jazz Pharmaceuticals position peaked at $3.15M in Q4 2023.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.